Efficacy and safety of sofosbuvir and daclatasvir with or without ribavirin in elderly patients with chronic hepatitis C virus infection
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Medical Virology"
DOI: 10.1002/jmv.25287
Abstract: Hepatitis C virus (HCV) infection is considered as a major public health problem that, worldwide, chronically affects 170 million people. Elderly patients are more likely than younger patients to have increased duration of infection, increased… read more here.
Keywords: efficacy safety; infection; sofosbuvir daclatasvir; elderly patients ... See more keywords
Sofosbuvir‐Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real‐life experience from the HEPATHER ANRS CO22 cohort
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Viral Hepatitis"
DOI: 10.1111/jvh.13321
Abstract: Sofosbuvir plus daclatasvir with or without ribavirin has demonstrated a high efficacy and an acceptable safety profile in clinical trials of patients infected with genotype 2 hepatitis Cvirus (HCV); however, there are currently no real‐world… read more here.
Keywords: without ribavirin; daclatasvir; sofosbuvir daclatasvir; daclatasvir without ... See more keywords